IP Library Patent Application 11571379
Patent Application
App. No. 11/571,379

Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/571,379
Abstract

The invention relates to a controlled release composition comprising a cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The controlled release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of cephalosporin-containing particles and the modified release component comprising a second population of cephalosporin-containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or bi-modal manner. Preferably, the cephalosporin is cefcapene pivoxil or a salt thereof which can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.

Claims (23)

1 . A controlled release antibiotic composition comprising a first population of cephalosporin-containing particles and at least one subsequent population of cephalosporin-containing particles, wherein the cephalosporin contained in the first population is substantially uncoated, and the subsequent population of cephalosporin-containing particles further comprises a modified release coating or, alternatively or additionally, a modified release matrix material, such that the composition following oral delivery to a subject delivers the cephalosporin in the first and subsequent populations in a pulsatile manner.

2 . The controlled release composition of claim 1 , wherein said cephalosporin is cefcapene pivoxil or a salt thereof.

3 . The composition according to claim 2 , wherein the first population comprises immediate-release particles and the subsequent population comprises modified-release particles.

4 . The composition according to claim 2 , wherein the first population comprises immediate-release particles and the formulation comprising the subsequent population is an erodable formulation.

5 . The composition according to claim 2 , wherein the formulation comprising the subsequent population is a diffusion controlled formulation.

6 . The composition according to claim 2 , wherein the formulation comprising the subsequent population is an osmotic controlled formulation.

7 . The composition according to claim 3 , wherein the modified release particles have a modified-release coating.

8 . The composition according to claim 3 , wherein the modified release particles comprise a modified-release matrix material.

9 . The compositions of claim 7 or 8 wherein said modified release particles are combined in formulation that releases said cefcapene pivoxil or salt thereof by erosion, diffusion or osmosis to the surrounding environment.

10 . The composition according to claim 9 , wherein at least one of the first and subsequent populations further comprises an enhancer.

11 . The composition according to claim 10 , wherein the amount of active ingredient contained in each of the first and subsequent populations is from about 0.1 mg to about 1 g.

12 . The composition according to claim 11 , wherein the first and subsequent populations have different in vitro dissolution profiles.

13 . The composition according to claim 12 , which in operation releases substantially all of the cefcapene pivoxil from the first population prior to release of the antibiotic from the subsequent population.

14 . The dosage form according to claim 13 comprising a blend of the particles of each of the first and subsequent populations contained in a hard gelatin or soft gelatin capsule.

15 . The dosage form according to claim 14 , wherein the particles of each of the populations are in the form of mini-tablets and the capsule contains a mixture of the mini-tablets.

16 . The dosage form according to claim 13 , in the form of a multilayer tablet comprising a first layer of compressed cefapene pivoxil or salt thereof-containing particles of the first population and another layer of compressed antibiotic-containing particles of the subsequent population.

17 . The dosage form according to claim 16 , wherein the first and subsequent populations of cefcapene pivoxil or salt thereof-containing particles are provided in a rapidly dissolving dosage form.

18 . The dosage form according to claim 17 , comprising a fast-melt tablet.

19 . A method for the treatment of bacterial infection comprising administering a therapeutically effective amount of a composition according to claim 2 .

20 . The composition according to claim 2 , wherein the modified-release particles comprise a pH-dependent polymer coating which is effective in releasing a pulse of the active ingredient following a time delay.

21 . The composition according to claim 20 , wherein the polymer coating comprises methacrylate copolymers.

22 . The composition according to claim 21 , wherein the polymer coating comprises a mixture of methacrylate and ammonio methacrylate copolymers in a ratio sufficient to achieve a pulse of the active ingredient following a time delay.

23 . The composition according to claim 22 , wherein the ratio of methacrylate to ammonio methacrylate copolymers is 1:1.

Assignments (5)
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2007
From: JENKINS, SCOTT; LIVERSIDGE, GARY
To: ELAN PHARMA INTERNATIONAL LIMITED
Reel/Frame 020150/0621 →